1. Introduction {#sec1}
===============

Cystic fibrosis (CF) is the most common autosomal recessive disorder in Caucasian populations. Patients with CF show a severe decline of pulmonary function related to chronic airway inflammation \[[@B1]\]. Recent studies suggest that inflammation occurs very early in pathogenesis and may even occur in the absence of infection; a deregulation of cytokine production and abnormal epithelial host defenses probably underlie and sustain inflammation \[[@B2]\]. A marked and persistent inflammatory process occurs very early in the course of CF and is present in mild as well as in stable disease \[[@B3]\]. Beyond the pulmonary phenotype, patients with CF frequently display alterations in peripheral muscle endurance, likely primarily due to physical inactivity.

The positive effects of physical exercise on body composition, insulin sensitivity, and blood glucose levels have been demonstrated in multiple morbid conditions, including different lung diseases \[[@B4], [@B5]\]. Respiratory muscle training, physiotherapy, and moderate physical activity have been shown to improve respiratory function in patients with CF \[[@B4]--[@B6]\]. Thus, it would be useful to identify biochemical mechanisms involved in such improvement.

Adiponectin is an abundant serum adipokine composing up to 0.05% of total circulating protein \[[@B7]\]. After its secretion by adipocytes, adiponectin oligomerizes in three forms: trimers of low molecular weight (LMW), hexamers of medium molecular weight (MMW), and multimers of high molecular weight (HMW) \[[@B8]\]. HMW multimers are the most active oligomers in their biological properties \[[@B8]\]. In non-obesity-related inflammatory disorders, adiponectin levels are increased \[[@B9]--[@B11]\].

Adiponectin plays a role in lung diseases and obesity; indeed, its receptors are expressed in lung epithelium; its serum levels are increased in patients with Chronic Obstructive Pulmonary Disease (COPD) \[[@B11]\]. In addition, data from *in vitro* studies on lung cells were consistent with an anti-inflammatory function of adiponectin \[[@B11], [@B12]\], and adiponectin-deficient mouse models develop lung function impairment and systemic inflammation \[[@B13], [@B14]\]. In the development and progression of lung cancer, a pathogenic role of adiponectin was defined by both *in vivo* and *in vitro* studies \[[@B15], [@B16]\].

Leptin is involved in various inflammatory diseases. In the lung, leptin exerts proinflammatory effects \[[@B17]\]. In the presence of lung inflammatory stimuli, increased leptin concentrations have been associated with symptom intensification and exacerbation \[[@B17]\].

Many studies suggest that exercise is associated with adiponectin and leptin levels in different metabolic diseases \[[@B17], [@B18]\], but to our knowledge, there are no studies on the effects of exercise on these two adipokines in patients with CF. In this study, we investigated the effects of 3 years of physical training on adiponectin and leptin serum concentrations in a cohort of CF patients compared to a control group of sedentary patients. We also measured correlations between serum adiponectin and leptin levels and biochemical and clinical parameters in the two patient groups. The results were further compared to those from a group of healthy subjects.

2. Materials and Methods {#sec2}
========================

2.1. Patients {#sec2.1}
-------------

The study population consisted of 116 CF patients who received diagnosis at the regional CF care center of Campania (Southern Italy). All patients who met the diagnostic criteria for CF \[[@B19]\] were over 18 years of age and had pathological SCL (*chloride* \> 60 *mEq*/*L*) and two class I-II *CFTR* mutations. Among the 116 patients, 58 regularly performed physical exercise in the last three years (exercise group) and 58 age-matched patients did not perform physical exercise in the last three years. Patients belonging to the exercise group performed physical exercises individually selected by and under the supervision of a team composed of a physician trained in CF, a nutritionist, and a physiotherapist. This team was responsible for monitoring each patient with particular attention to his/her hydration and type of physical activity, to prevent salt depletion syndrome or other complications. Furthermore, the team monitored the compliance of the patients with exercise training. Informed consent was obtained from all participants. Ninety-eight healthy volunteers aged 31.1 ± 7.6 years constituted the control group (*BMI* = 23.4 ± 3.0). The research protocol was conducted in accordance with the principles of the Helsinki II Declaration. According to the current legislation in Italy, we obtained informed consent from each subject for anonymous use of clinical data for research purposes.

2.2. Clinical Evaluation {#sec2.2}
------------------------

Sweat chloride levels were tested as previously described \[[@B20]\] and a panel of *CFTR* mutations was screened \[[@B21]\]. The best FEV1, expressed as percentage of predicted value for age, according to standardized reference equations for spirometry \[[@B19]\] were recorded. Airway colonization by *Pseudomonas aeruginosa*, pancreatic sufficiency (PS), and liver disease (CFLD) was assessed as previously described \[[@B6], [@B22]\]. Diagnosis of CFRD was made according to the American Diabetes Association criteria \[[@B23]\].

2.3. Anthropometric Measurements {#sec2.3}
--------------------------------

We recorded the height, weight, BMI, waist circumference, and upper arm circumference of CF patients and healthy controls as previously described \[[@B6]\]. Body weight was measured in a fasting state in the morning with a mechanical balance (±0.1 kg, SECA 700, Hamburg DE). BMI was calculated as body weight divided by height squared (kg/m^2^) with categories in accordance with the World Health Organization guidelines \[[@B24]\]. To define subjects with alterations in BMI and circumferences, we used reference intervals normalized to the age of each patient \[[@B24]\].

2.4. Biochemical Parameters {#sec2.4}
---------------------------

Blood samples (*n* = 214) were collected from the participants after an overnight fast, and serum samples were separated. Serum albumin, insulin, C-reactive protein, glucose, total cholesterol, HDL and LDL cholesterol, and triglycerides were measured as previously described \[[@B6]\]; all assays were performed with an automated biochemistry analyser (Architect *ci*16200 Integrated System, Abbott Diagnostics, Rome, Italy). The HOMA index was calculated as *fasting* *glucose* × *fasting* *insulin*/22.5 \[[@B23]\]. Concentrations of total adiponectin in serum were measured in triplicate by an enzyme-linked immunosorbent assay (ELISA) as previously described \[[@B25]\]. A Sandwich-ELISA assay was used to measure leptin concentration in serum samples (Elabscience, Houston, Texas, USA).

2.5. Western Blotting Analysis {#sec2.5}
------------------------------

Serum samples from all participants were quantified for total proteins by Bradford assay (Bio-Rad, Hercules, CA, USA), and 10 *μ*g of total protein was heated in 1X Laemmli buffer at 95°C for 10 min and loaded on 10% SDS-PAGE gels as previously described \[[@B11]\]. The immunoblots were developed by ECL (Amersham Biosciences, Piscataway, NJ, USA) with the use of Kodak BioMax Light film, digitalised with a scanner (1200 dpi), and analysed by densitometry with ImageJ software (<https://imagej.nih.gov/ij/>). Each sample was tested three times in duplicate.

2.6. Statistical Analysis {#sec2.6}
-------------------------

All data are expressed as *means* ± *SD*. The Kolmogorov-Smirnov test was used to test the normality of distributions. Student\'s *t*-test or the Mann-Whitney *U* test for independent samples were used to compare parametric and nonparametric numerical data, respectively. Frequencies of categorical variables were compared by Chi-square tests. Adiponectin serum concentrations were correlated by Pearson\'s or Spearman\'s rho tests, according to data distribution. A *p* value \< 0.05 was considered statistically significant. Multiple comparisons on western blotting experiments were performed by ANOVA tests. All statistical analyses were performed with the Statistical Package for Social Sciences software for Windows (SPSS Inc.).

3. Results {#sec3}
==========

3.1. Anthropometric and Biochemical Features of Patients with CF {#sec3.1}
----------------------------------------------------------------

Anthropometric and serum biochemical profiles of CF patients and control healthy subjects are reported in [Table 1](#tab1){ref-type="table"}.

All subjects were matched for age and sex. Data are shown in [Table 1](#tab1){ref-type="table"}. BMI values were significantly lower in patients with CF compared to controls. CF patients had significantly lower cholesterol lipid and significantly higher glucose levels than controls. Adiponectin serum levels were increased in CF patients *vs.* controls, while leptin levels are significantly decreased in CF patients *vs.* controls.

After the comparison to healthy subjects, we divided the CF patients into two age- and sex-matched subgroups and compared anthropometrical, biochemical, and disease-specific parameters between patients that regularly performed physical exercise in the last three years and sedentary patients. [Table 2](#tab2){ref-type="table"} shows that these two subgroups (active and sedentary) significantly differed for both FEV1% decrease/year and FEV1% decrease. In the active group, triglyceride levels were significantly lower than in the sedentary group. Serum adiponectin levels were significantly lower in active versus sedentary CF patients, respectively. On the contrary, leptin levels are slightly decreased in sedentary CF patients *vs.* active patients, although the difference is not significant. Finally, C-reactive protein levels were significantly lower in the active group than in the sedentary group.

3.2. Adiponectin Correlations to Biochemical and Clinical Parameters in CF Patients {#sec3.2}
-----------------------------------------------------------------------------------

[Table 3](#tab3){ref-type="table"} shows the correlations observed between adiponectin, biochemical, and FEV parameters in active and sedentary CF patients. Adiponectin correlated negatively with both FEV1% decrease per year as well as with FEV% decrease only in the active group. In addition, adiponectin correlated negatively with lipid biomarkers; in particular, we observed a negative correlation with total cholesterol (chol), LDL, and non-HDL chol in both groups. Finally, serum triglyceride levels correlated negatively with adiponectin levels only in the active group.

3.3. Adiponectin Oligomerization State Analysis in Serum by Western Blotting {#sec3.3}
----------------------------------------------------------------------------

The distribution of serum adiponectin in sedentary and active CF patients was analysed and compared to the healthy control group by western blot ([Figure 1](#fig1){ref-type="fig"}). Three bands corresponding to HMW (≥250 kDa), MMW (180 kDa), and LMW (70 kDa) oligomers were evident in serum from both controls and patients ([Figure 1(a)](#fig1){ref-type="fig"}). The densitometric evaluation of adiponectin oligomers in serum showed an increased expression of the HMW, MMW, and LMW oligomers in CF patients compared to controls ([Figure 1(b)](#fig1){ref-type="fig"}) (*p* \< 0.05). On the other hand, adiponectin oligomers were only slightly more highly expressed (not statistically significant) in active CF patients compared to healthy controls but significantly lower expression compared to sedentary CF patients.

4. Discussion {#sec4}
=============

Serum adiponectin levels were significantly higher while leptin levels were significantly decreased in CF patients compared to healthy controls. Furthermore, patients with CF that performed 3 years of regular physical activity had adiponectin concentrations significantly lower than those of sedentary patients; in parallel, serum C-reactive protein levels were significantly lower in the active CF group than in the sedentary CF group. Interestingly, in the active CF group, adiponectin levels were negatively correlated with FEV1% decrease per year, FEV1% decrease, and serum CRP. In addition, adiponectin levels were negatively correlated with lipid profiles in the entire cohort of CF patients. Regarding leptin levels, patients with CF that performed 3 years of regular physical activity had increased levels compared to sedentary patients, although data are not significant.

CF is characterized by systemic inflammation associated with progressive airflow obstruction (FEV1), airway neutrophilic inflammation, and recurrent exacerbations; these phenotypical and pathologic features are shared with COPD \[[@B10]\]. In this context, looking at adiponectin and leptin as important modulators of inflammatory processes implicated in airway pathophysiology, we found that serum levels of adiponectin were significantly increased in CF patients compared to healthy controls while leptin levels were significantly decreased in the total cohort of CF patients compared to healthy controls. Moriconi et al. reported increased serum adiponectin in CF patients than in controls, independently of other confounders \[[@B26]\]. In line with these results, significantly increased adiponectin concentrations and a direct correlation to the severity of disease have been observed in patients affected by COPD \[[@B11], [@B27]--[@B30]\]. In addition, a relationship between adiponectin concentration and lung function decline has been reported \[[@B31]\]. More recently, an involvement of adiponectin has been described during the pathogenesis of emphysema \[[@B16], [@B28]\]. Contrasting results are observed for leptin levels in patients with CF \[[@B32]--[@B36]\].

Previously, we reported that long-term physical exercise had significantly beneficial effects on FEV1% decline, BMI, waist and arm circumferences, and lipid and glucose metabolism in CF patients \[[@B6]\]. In the present study, we examined the effects of physical activity on adiponectin and leptin levels in such patients. Interestingly, we observed that the adiponectin levels significantly decreased with 3 years of regular exercise while leptin levels are increased, although not significant. In particular, in patients with CF, long-term physical exercise produces both an amelioration of the pulmonary phenotype and an improvement of systemic inflammation as demonstrated by the FEV1% decrease, by CRP and adiponectin reduction, and the increase of leptin serum levels. Furthermore, the negative correlation between adiponectin and FEV1% decrease/year and FEV1% decrease observed in the active group of CF patients is consistent with this hypothesis. On the other hand, adiponectin levels are usually elevated in classic chronic inflammatory/immune diseases such as multiple sclerosis, common variable immunodeficiency, and inflammatory bowel disease \[[@B9], [@B37]--[@B39]\]. In this context, our data highlight the key role of adiponectin in lung pathologies as a crosstalk between lung and adipose tissue. Our data also underline a correlation between adiponectin and the lipid profile of CF patients. In our cohort of CF patients performing regular exercise for 3 years, physical training induces the mobilization of triglycerides, improving the metabolic profile that correlates with adiponectin levels. Panagopoulou et al. previously demonstrated that adiponectin is higher in CF patients than in controls with lower levels in malnourished young patients and higher in patients with normal nutrition. The authors concluded that this may be attributed to the energy deficit due to the disease \[[@B40]\]. Ziai et al. demonstrated that the association between total adiponectin and glucose and insulin metabolism is different in CF patients compared to controls, although they found similar levels of adiponectin between CF patients and controls \[[@B33]\].

In literature, conflicting data are present on leptin concentrations and its role in CF patients \[[@B32]--[@B36]\]. To our knowledge, no data about physical activity on leptin levels are reported. In this study, we observed that leptin levels are slightly increased in active CF vs. sedentary patients. These results are in line with previously reported data that observed different concentrations of leptin according to CF disease phenotype and concluded that severe CF patients had significantly decreased leptin compared to controls \[[@B35]\]. This data indicated that leptin may be a further indicator of inflammatory status in patients with CF. However, a limitation of the study is represented by the limited number of CF patients and controls analysed.

5. Conclusion {#sec5}
=============

In conclusion, our results indicate that in CF patients, long-term physical exercise ameliorates the pulmonary phenotype and improves the metabolic profile and systemic inflammation as shown by serum CRP reduction, adiponectin decrease, and leptin increase. Recently, immunometabolic pathomechanisms have been identified as important factors determining and modulating lung function and disease \[[@B41]\]. Therefore, both adipokines appear to be an attractive biomarker for monitoring CF progression. Further studies are needed to define the molecular mechanisms through which adiponectin and leptin modulates such effects.
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![Adiponectin HMW oligomer levels are decreased by long-term physical activity. (a) Representative images from blots of serum adiponectin oligomers (HMW, MMW, and LMW) from healthy controls, CF sedentary patients, and CF active patients; (b) quantification of adiponectin oligomers in serum samples. Each sample was tested three times in duplicate, and values are reported as percentage compared to controls. Multiple comparisons were performed by ANOVA.](MI2019-2153934.001){#fig1}

###### 

Sex distribution, anthropometric data, and serum biochemical parameters in patients with CF and in control subjects, CN (mean values and standard deviation).

                                  CN subjects (*n* = 98)   CF patients (*n* = 116)   *p* value
  ------------------------------- ------------------------ ------------------------- -------------
  Age (years)                     31.1 (7.6)               30.9 (8.7)                *n.s.* ^∗^
  Sex male/female                 55/43                    59/57                     *n.s.* ^∗∗^
  Body mass index (kg/m^2^)       23.4 (3.0)               22.4 (3.6)                *.001* ^∗^
  Total chol (mg/dL)              190.2 (35.3)             140.9 (36.6)              *.000*
  Triglycerides (mg/dL)           86.5 (53.7)              79.6 (29.5)               *n.s.* ^∗^
  HDL chol (mg/dL)                56.6 (15.2)              47.0 (14.3)               *.000*
  LDL chol (mg/dL)                114.8 (30.2)             78.0 (28.0)               *.000*
  Non-HDL chol (mg/dL)            133.6 (35.9)             93.9 (31.2)               *.000*
  Tot/HDL chol ratio (%)          3.6 (1.2)                3.1 (0.8)                 *.010* ^∗^
  Non-HDL/HDL chol ratio (%)      2.6 (1.2)                2.1 (0.8)                 *.010* ^∗^
  Serum fasting glucose (mg/dL)   83.2 (12.8)              90.8 (17.6)               *.000* ^∗^
  Albumin (g/dL)                  4.7 (0.4)                4.3 (0.4)                 *.000*
  Adiponectin (*μ*g/mL)           10.2 (1.6)               13.2 (2.2)                *.000*
  Leptin (ng/mL)                  12.0 (6.1)               9.2 (11.2)                *.003* ^∗^

*p* values by *t*-test, ^∗^Mann-Whitney *U* test or ^∗∗^Chi-square test; *n.s*.: not significant.

###### 

Sex distribution, anthropometric data, biochemical parameters, and FEV values in patients with CF divided on the basis of physical activity (mean values and standard deviation).

                                  CF physical activity group (*n* = 58)   CF sedentary group (*n* = 58)   *p* value
  ------------------------------- --------------------------------------- ------------------------------- -------------
  Age (years)                     30.7 (8.3)                              31.1 (9.2)                      *n.s.*
  Sex (male/female)               29/29                                   30/28                           *n.s.* ^∗∗^
  Body mass index (kg/m^2^)       22.4 (3.2)                              22.4 (4.0)                      *n.s.* ^∗^
  Waist circumference (cm)        80.0 (8.9)                              81.5 (9.7)                      *n.s.*
  Hip circumference (cm)          93.4 (7.6)                              92.8 (9.1)                      *n.s.*
  Waist/hip ratio (%)             86.2 (8.9)                              88.1 (8.4)                      *n.s.*
  FEV1% decrease/year             0.46 (3.58)                             1.13 (5.01)                     *.044*
  FEV1% decrease (%)              0.87 (4.77)                             1.03 (8.02)                     *.008*
  Total cholesterol               140.3 (37.3)                            141.6 (36.2)                    *n.s.*
  Triglycerides (mg/dL)           72.7 (20.6)                             86.6 (35.2)                     *.012*
  Serum fasting glucose (mg/dL)   90.0 (21.4)                             91.5 (13.1)                     *n.s.* ^∗^
  Insulinemia (mg/dL)             8.1 (7.2)                               10.5 (9.2)                      *n.s.* ^∗^
  HOMA-IR                         1.8 (1.5)                               2.4 (2.1)                       *n.s.* ^∗^
  FGIR                            17.5 (10.3)                             14.6 (10.3)                     *n.s.*
  Adiponectin (*μ*g/mL)           12.8 (2.1)                              13.7 (2.2)                      *.047*
  Leptin (ng/mL)                  10.8 (13.7)                             7.7 (8.1)                       *n.s.* ^∗^
  C-reactive protein (mg/L)       3.65 (3.98)                             6.33 (8.52)                     *.048*

*p* values by *t*-test, ^∗^Mann-Whitney *U* test or ^∗∗^Chi-square test; n.s.: not significant.

###### 

The statistically serum adiponectin correlations in CF patients, divided according to physical activity.

  -------------------------------------------------------------------------
                        CF physical activity group\   CF sedentary group\
                        (*n* = 50)                    (*n* = 49)
  --------------------- ----------------------------- ---------------------
  FEV1% decrease/year   *.013 (-)*                    

  FEV1% decrease (%)    *.025 (-)*                    

  Total cholesterol     *.024 (-)*                    *.022 (-)*

  Triglycerides         *.003 (-)*                    

  LDL cholesterol       .*023 (-)*                    *.024 (-)*

  Non-HDL cholesterol   *.013 (-)*                    *.043 (-)*

  C-reactive protein    *.011 (+)* ^∗^                
  -------------------------------------------------------------------------

*p* values by Pearson correlation or ^∗^by Spearman\'s rho correlation.
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